However, in ccRCC cells, the expression of wild-type p53 is abnormally low, primarily because of the activation of MDM2 by mTOR, leading to ubiquitination and degradation of wild-type p53, thereby promoting ccRCC (Roe and Youn, 2006). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.